000			03619nam a22003618i 4500
001			CR9780511712265
003			UkCbUP
005			20200124160315.0
006			m|||||o||d||||||||
007			cr||||||||||||
008			100225s2010||||enk o ||1 0|eng|d
020			_a9780511712265 (ebook)
020			_z9780521895330 (hardback)
040			_aUkCbUP _beng _erda _cUkCbUP
050	0	0	_aRM333.5 _b.A58 2010
082	0	0	_a616.89/8061 _222
245	0	0	_aAntipsychotic trials in schizophrenia : _bthe CATIE project / _cedited by T. Scott Stroup, Jeffrey A. Lieberman.
264		1	_aCambridge : _bCambridge University Press, _c2010.
300			_a1 online resource (xvii, 312 pages) : _bdigital, PDF file(s).
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
500			_aTitle from publisher's bibliographic system (viewed on 05 Oct 2015).
505	8		_aMachine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index.
520			_aAntipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.
650		0	_aAntipsychotic drugs _xTesting.
650		0	_aSchizophrenia _xChemotherapy.
610	2	0	_aCATIE Project.
700	1		_aStroup, T. Scott, _d1960- _eeditor.
700	1		_aLieberman, Jeffrey A., _d1948- _eeditor.
776	0	8	_iPrint version: _z9780521895330
856	4	0	_uhttps://doi.org/10.1017/CBO9780511712265
999			_c521366 _d521364